Literature DB >> 9737543

NT-3 attenuates functional and structural disorders in sensory nerves of galactose-fed rats.

A P Mizisin1, M W Kalichman, M Bache, K C Dines, P S DiStefano.   

Abstract

The present study investigated the effect of NT-3, a neurotrophin expressed in nerve and skeletal muscle, on myelinated fiber disorders of galactose-fed rats. Adult, female Sprague-Dawley rats were fed diets containing complete micronutrient supplements and either 0% D-galactose (control) or 40% D-galactose. Treated controls received 20 mg/kg NT-3 and treated galactose-fed rats received 1, 5, or 20 mg/kg NT-3 three times per week by subcutaneous injections. After 2 months, sciatic and saphenous sensory nerve conduction velocity (SNCV) and sciatic motor nerve conduction velocity (MNCV) were measured and the sciatic, sural, peroneal and saphenous nerves and dorsal and ventral roots processed for light microscopy. Treatment of control animals with NT-3 had no effect on any functional or structural parameter. Compared to control values, galactose feeding induced a sensory and motor nerve conduction deficit and a reduction in axonal caliber. Treatment with 5 and 20 mg/kg NT-3 ameliorated deficits in sciatic and saphenous SNCV in galactose-fed rats but had no effect on the MNCV deficit. NT-3 treatment also attenuated the decrease in mean axonal caliber in the dorsal root and sural nerve but not in the saphenous nerve, ventral root and peroneal nerve. These observations show that NT-3 can selectively attenuate the sensory conduction deficit of galactose neuropathy in a dose-dependent manner that depends only in part on restoration of axonal caliber of large-fiber sensory neurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737543     DOI: 10.1097/00005072-199809000-00001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  6 in total

1.  Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice.

Authors:  J A Christianson; J M Ryals; M S Johnson; R T Dobrowsky; D E Wright
Journal:  Neuroscience       Date:  2006-12-16       Impact factor: 3.590

Review 2.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

3.  Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of niemann-pick disease type C.

Authors:  Jessica H Bagel; Tracey U Sikora; Maria Prociuk; Jill P Pesayco; Andrew P Mizisin; G Diane Shelton; Charles H Vite
Journal:  J Neuropathol Exp Neurol       Date:  2013-03       Impact factor: 3.685

4.  Erythropoietin both protects from and reverses experimental diabetic neuropathy.

Authors:  Roberto Bianchi; Belgin Buyukakilli; Michael Brines; Costanza Savino; Guido Cavaletti; Norberto Oggioni; Giuseppe Lauria; Monica Borgna; Raffaella Lombardi; Burak Cimen; Ulku Comelekoglu; Arzu Kanik; Cengiz Tataroglu; Anthony Cerami; Pietro Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

5.  AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease).

Authors:  Allison M Bradbury; Mohammed A Rafi; Jessica H Bagel; Becky K Brisson; Michael S Marshall; Jill Pesayco Salvador; Xuntain Jiang; Gary P Swain; Maria L Prociuk; Patricia A ODonnell; Caitlin Fitzgerald; Daniel S Ory; Ernesto R Bongarzone; G Diane Shelton; David A Wenger; Charles H Vite
Journal:  Hum Gene Ther       Date:  2018-03-14       Impact factor: 4.793

Review 6.  Racial Differences in Pain, Nutrition, and Oxidative Stress.

Authors:  Larissa J Strath; Robert E Sorge
Journal:  Pain Ther       Date:  2022-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.